TriSalus Life Sciences, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $-137.4M | $50.9K |
| Jun 2022 | — | $-146.0M | $69.2K |
| Sep 2022 | — | $-153.9M | $207.6K |
| Dec 2022 | — | $-177.1M | $9.4M |
| Mar 2023 | — | $-184.5M | $136.8K |
| Jun 2023 | — | $-198.4M | $104.0K |
| Sep 2023 | — | $8.3M | $21.4M |
| Dec 2023 | $0 | $-27.1M | $11.8M |
| Mar 2024 | — | $-36.0M | $4.0M |
| Jun 2024 | $21.3M | $-25.3M | $16.5M |
| Sep 2024 | $21.7M | $-20.4M | $11.3M |
| Dec 2024 | $22.1M | $-25.9M | $8.5M |
| Mar 2025 | $31.7M | $-34.4M | $13.0M |
| Jun 2025 | $32.3M | $-19.4M | $26.5M |
| Sep 2025 | $32.8M | $-26.7M | $22.7M |
| Dec 2025 | $33.0M | $-33.9M | $20.4M |
| Mar 2026 | $33.1M | $12.8M | $56.6M |
| Jun 2026 | $33.1M | $6.6M | $46.3M |